メインコンテンツにスキップ

Bloomberg Podcast: 広がり続けるオミクロン

Dec 02, 2021 Hosts Alix Steel and Guy Johnson speak with Opinion Columnist Marcus Ashworth, BI Director of research Sam Fazeli, European Oil Team Leader James Herron, Certara CEO William Feehery, Grab Co-Founder Hooi Ling Tan

CertaraのSimcyp™新型コロナウイルス感染症ワクチンモデルがR&D 100アワードを受賞

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ – 2021年10月25日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in … Continued

COVID-19 Vaccines: US Approvals Vs Authorization as of 2021年10月11日

There is a lot of misinformation about whether or not the COVID-19 vaccines have “full” FDA approval or Emergency Use Authorization (EUA). The words approval and authorization are often used incorrectly; they are not interchangeable. On 2020年3月27日, the Secretary of health and Human Services (HHS) issued a declaration that there is a public … Continued

How COVID-19 has fundamentally changed clinical research in global health

By: Jay J HParkMSc, RobinMoggPhD, Gerald ESmithMSc, EtheldredaNakimuli-MpunguPhD, FyezahJehanMBBS, Craig RRaynerPharmD, JeanineCondoPhD, Eric HDecloedtPhD, ProfJean BNachegaPhD, GilmarReisPhD, ProfEdward, JMillsFRCP COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have been … Continued

新型コロナウイルス感染症の各段階について無作為化臨床試験の新たに発生したエビデンスの状況:グローバル試験登録の系統的な審査

Alison Dillman,1 Michael J Zoratti,2 Jay JH Park,3 Grace Hsu,2 Louis Dron,2 Gerald Smith,2 Ofir Harari,2 Craig R Rayner,4 Noor-E Zannat,2 Alind Gupta,2 Eric Mackay,5 Paul Arora,6 Zelyn Lee,7 Edward J Mills2 A multitude of randomized controlled trials (RCTs) have emerged in response to the novel coronavirus disease (COVID-19) pandemic. Understanding the distribution of trials among various settings is important to guide future research priorities and efforts. The … Continued

How COVID-19 Affects Stakeholder Engagement & Value Communication

By Tom Hemy The COVID-19 pandemic has made the development and commercialization of pharmaceuticals and medical devices even more challenging. For example, in the value communication and stakeholder engagement area, many field representatives found themselves refused entry to hospitals and surgeries and unable to meet in-person with payers, doctors, and other key stakeholders. These meetings … Continued

1 of 3
Powered by Translations.com GlobalLink OneLink Software